Concepedia

Conn Harrington

CH

Statistics

Publications

9

Citations

1.3K

H-Index

9

Active since

2011

Affiliations

Janssen (Belgium)(Current)

Research Triangle Park Foundation

GlaxoSmithKline (United States)

University of Nebraska Medical Center

GlaxoSmithKline (Canada)

Conn Harrington is an author at Janssen (Belgium) specializing in pharmacology, clinical pharmacology, and long-acting antiretroviral therapy.

Publications per year

2011–2024

9

Publications

9

Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression

Susan Swindells, Jaime Andrade‐Villanueva, Gary Richmond et al. · New England Journal of Medicine · 2020 · 565 citations · Full text

, , +17

Rosiglitazone Does Not Improve Cognition or Global Function when Used as Adjunctive Therapy to AChE Inhibitors in Mild-to-Moderate Alzheimers Disease: Two Phase 3 Studies

Conn Harrington, Sharon Sawchak, Carl Chiang et al. · Current Alzheimer Research · 2011 · 193 citations

, , +17

Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials

Giuliano Rizzardini, Edgar T. Overton, Chloe Orkin et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2020 · 149 citations · Full text

, , +17

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Edgar T. Overton, Gary Richmond, Giuliano Rizzardini et al. · Clinical Infectious Diseases · 2023 · 124 citations · Full text

, , +17

A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of the H<sub>3</sub> Receptor Antagonist, GSK239512 as a Monotherapy in Subjects with Mild-to-Moderate Alzheimer’s Disease

Richard Grove, Conn Harrington, Andreas Mahler et al. · Current Alzheimer Research · 2014 · 109 citations

, , +17

1–5 of 9